

Support for the Road Ahead

The program designed for you and your care partner(s)
during CARVYKTI® (ciltacabtagene autoleucel) treatment.



Are you eligible?
Let's find out.


MYCARVYKTI®
Patient Support Program

Patients prescribed CARVYKTI® may be eligible for the MyCARVYKTI® Patient Support Program

MyCARVYKTI® is a patient support program designed to support eligible patients and their care partner(s) with travel-related expenses during CARVYKTI® treatment at an Activated Treatment Center.

The program may offer support with:



TRANSPORTATION



LODGING



MEALS AND OUT-OF-POCKET TRAVEL EXPENSES

You may receive this support for leukapheresis, infusion, and bridging therapy if administered at the Activated Treatment Center where you are receiving CARVYKTI® treatment.*

*MyCARVYKTI® support is available only when you and your care partner(s) remain at or near the Activated Treatment Center during the above treatment trips.



Transportation

MyCARVYKTI® may provide assistance with ground or air transportation costs to and from the CARVYKTI® Activated Treatment Center for each approved treatment trip. Transportation support may include mileage reimbursement, bus, rail, or air travel.



Lodging

MyCARVYKTI® may cover the cost of lodging accommodations near the Activated Treatment Center. All arrangements will be made by the MyCARVYKTI® travel provider. Travel support is available 24/7, 365 days a year, to support eligible patients and their care partner(s).



Meals and Out-of-Pocket Travel Expenses

MyCARVYKTI® may reimburse a daily per diem for costs related to meals and other out-of-pocket travel expenses for approved trips related to CARVYKTI® treatment.

Please read Important Safety Information located on pages 5-6 and read full [Prescribing Information](#), including Boxed Warning, for CARVYKTI®.



We are here to help. If you have questions, call **800-559-7875**, option 1, Monday through Friday, 8:00 AM to 8:00 PM ET

Who is eligible for MyCARVYKTI®?

- To participate in MyCARVYKTI®, you must have been prescribed CARVYKTI® and meet distance and income eligibility criteria. A care partner may be required to accompany you during infusion and monitoring in order to receive support. Participants must reside in the United States or its territories.

Support benefits that are provided by your health insurance plan and Activated Treatment Center must be used prior to utilizing benefits from the program, as the program does not provide duplicative support.

How do I enroll in MyCARVYKTI®?

- You can speak with your healthcare team for a referral to the MyCARVYKTI® Patient Support Program

OR

- You can contact the MyCARVYKTI® Patient Support Program directly at **800-559-7875, option 1**, Monday through Friday, 8 AM to 8 PM ET.



DEDICATED PATIENT SUPPORT



Our dedicated Patient Support Specialists will assist you with the application process. In fact, your enrollment can easily be completed over the phone.

- **We encourage** patients to reach out to the program as soon as they have been prescribed CARVYKTI® treatment so we can determine eligibility for our support offerings.
- **We offer** real-time translation support when needed to ensure that every eligible patient receives assistance throughout their treatment journey.

Please read Important Safety Information located on pages 5-6 and read full [Prescribing Information](#), including Boxed Warning, for CARVYKTI®.



We are here to help. If you have questions, call **800-559-7875, option 1**, Monday through Friday, 8:00 AM to 8:00 PM ET

Do I need insurance to participate in MyCARVYKTI®?

- MyCARVYKTI® may be an option for you even if you do not have health insurance. The program is available to eligible patients regardless of insurance coverage, including commercial, private, or government-funded healthcare. We encourage patients who have decided to proceed with CARVYKTI® treatment to reach out to determine their eligibility as soon as possible.

For additional details about MyCARVYKTI®, see *Program Rules* included in this brochure.

Do you work directly with my Activated Treatment Center?

- Our dedicated Patient Support Specialists work directly with your healthcare professionals to ensure travel logistics are coordinated to help support you through your treatment journey.

What is the role of my care partner?

- A care partner may be required to accompany the patient during infusion and monitoring. The MyCARVYKTI® Patient Support Program may be able to provide travel support for designated care partners for transportation, lodging, and out-of-pocket expenses related to meals and other travel expenses for approved treatment trips.



GETTING STARTED

To find out if you are eligible, contact the MyCARVYKTI® program directly at **1-800-559-7875, option 1**, Monday through Friday from 8 AM to 8 PM ET as soon as you have been prescribed CARVYKTI®.

Enrollment Support

You will be assigned a dedicated Patient Support Specialist who will initiate the enrollment process and work with you to determine eligibility.

Please read Important Safety Information located on pages 5-6 and read full [Prescribing Information](#), including Boxed Warning, for CARVYKTI®.



We are here to help. If you have questions, call **800-559-7875, option 1**, Monday through Friday, 8:00 AM to 8:00 PM ET

MyCARVYKTI® Patient Support Program Rules

Am I Eligible?

The MyCARVYKTI® Patient Support Program (the “Program”) is sponsored by Johnson & Johnson and Legend Biotech. The Program offers travel support to patients who meet income and distance eligibility requirements and their care partners. It may provide assistance with transportation, lodging, and out-of-pocket costs related to meals and other travel expenses associated with CARVYKTI® (ciltacabtagene autoleucl) treatment at a CARVYKTI® Activated Treatment Center. The Program does not cover costs for medication or administration. Support benefits that are provided by your health insurance plan and Activated Treatment Center must be used prior to utilizing benefits from the Program, as the Program will not provide duplicative support benefits. To see if you might qualify for assistance, please contact a MyCARVYKTI® Patient Support Specialist at 1-800-559-7875, Monday through Friday, 8:00 AM to 8:00 PM ET.

Eligibility Requirements

- This Program is only available for patients who are receiving CARVYKTI® treatment in accordance with the FDA-approved Prescribing Information at an Activated Treatment Center and their care partners
- Patients and care partners must reside in the United States and its territories in order to participate in the MyCARVYKTI® Patient Support Program
- This Program is available to all eligible patients, with or without medical insurance
- If you apply to enroll in the MyCARVYKTI® Patient Support Program, it is important you understand that you will be asked to provide personal information that may include your name, address, phone number, email address, and information related to your prescription insurance and treatment. This information is necessary to permit Johnson & Johnson, and companies that work with Johnson & Johnson, including our affiliates and our service providers, to fulfill your request to enroll in the MyCARVYKTI® Patient Support Program. Johnson & Johnson will not share your information with anyone else except as required by law
- By participating in the MyCARVYKTI® Patient Support Program, you confirm that you have read, understand, and agree to the Program requirements shown on this page
- The Program is in no way an extension of medical treatment provided by healthcare professionals to individual patients. You may discontinue your participation at any time by calling 1-800-559-7875, Monday through Friday, 8:00 AM to 8:00 PM ET
- Program terms will expire at the end of each calendar year. Program subject to change or discontinuation without notice, including in specific states

What is CARVYKTI® (ciltacabtagene autoleucl)?

- CARVYKTI® is a treatment used for adult patients who have cancer of the bone marrow called multiple myeloma. It is used when at least one other treatment has not worked or has stopped working
- CARVYKTI® is a medicine made from your own white blood cells, which have been changed (genetically modified) to recognize and attack your multiple myeloma cells

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about CARVYKTI®?

CARVYKTI® may cause side effects that are severe or life-threatening and can lead to death. Call your healthcare provider or get emergency help right away if you get any of the following:

- fever (100.4°F/38°C or higher)
- difficulty breathing
- chills or shaking chills
- very low blood pressure
- fast or irregular heartbeat
- dizziness/lightheadedness
- persistent or severe diarrhea, abdominal pain, and weight loss
- effects on your nervous system, some of which can occur days or weeks after you receive the infusion, and may initially be subtle such as:
 - feeling confused, less alert, or disoriented; having difficulty speaking or slurred speech; having difficulty reading, writing, and understanding words; memory loss
 - loss of coordination affecting movement and balance, slower movements, changes in handwriting
 - personality changes, including a reduced ability to express emotions, being less talkative, disinterested in activities, and reduced facial expression
 - tingling, numbness, and pain of hands and feet, difficulty walking, leg and/or arm weakness, and difficulty breathing
 - facial numbness, difficulty moving muscles of face and eyes

It is important that you tell your healthcare providers that you have received CARVYKTI® and to show them your CARVYKTI® Patient Wallet Card. Your healthcare providers may give you other medicines to treat your side effects.

Before you receive CARVYKTI®, tell your healthcare provider about all your medical conditions, including if you have:

- Current or past neurologic problems (such as seizures, stroke, new or worsening memory loss)
- Lung or breathing problems
- Heart problems
- Liver problems
- Kidney problems
- A recent or active infection
- Low blood counts

Important Safety Information continues →

Please read full [Prescribing Information](#), including [Boxed Warning](#), for CARVYKTI®.

IMPORTANT SAFETY INFORMATION (cont)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive CARVYKTI®?

- CARVYKTI® is made from your own white blood cells, so your blood will be collected by a process called “leukapheresis” (loo-kah-fur-ee-sis). The procedure can take 3 to 6 hours and may need to be repeated.
- Your white blood cells are sent to a manufacturing center to make CARVYKTI®. It takes about 4-5 weeks from the time your cells are received at the manufacturing site and are available to be shipped back to your healthcare provider, but the time may vary.
- While CARVYKTI® is being made, you may get other medicines to treat the multiple myeloma. This is so your multiple myeloma does not get worse.

Before you get CARVYKTI®, your healthcare provider will give you chemotherapy for 3 days to prepare your body.

Thirty to 60 minutes before you are given CARVYKTI®, you may be given other medicines. These may include:

- medicines for an allergic reaction (antihistamines)
- medicines for fever (such as acetaminophen)

When your CARVYKTI® is ready, your healthcare provider will give CARVYKTI® to you through a catheter (tube) placed into your vein (intravenous infusion). Your dose of CARVYKTI® will be given in one infusion bag. The infusion usually takes approximately 30-60 minutes.

After getting CARVYKTI®, you will be monitored at the certified healthcare facility where you received your treatment for at least 7 days after the infusion.

You should plan to stay close to the location where you received your treatment for at least 2 weeks. Your healthcare provider will check to see that your treatment is working and help you with any side effects that may occur. You may be hospitalized if you develop serious side effects until your side effects are under control and it is safe for you to leave the hospital.

Your healthcare provider will want to do blood tests to follow your progress. It is important that you have your blood tested. If you miss an appointment, call your healthcare provider as soon as possible to reschedule.

What should I avoid after receiving CARVYKTI®?

- Avoid driving for at least 2 weeks after you get CARVYKTI®
- You must not be given certain vaccines called live vaccines for some time before and after CARVYKTI® treatment. Talk to your healthcare provider if you need to have any vaccinations
- Do not donate blood, organs, tissues, or cells for transplantation

What are the possible or reasonably likely side effects of CARVYKTI®?

The most common side effects of CARVYKTI® include:

- fever (100.4°F/38°C or higher), chills
- dizziness/lightheadedness
- headache, muscle or joint pain, feeling very tired
- altered mental state, confusion

- infections
- low levels of antibodies (immunoglobulins) in the blood
- cough, being short of breath
- diarrhea, nausea, decreased appetite, constipation
- fast or irregular heartbeat
- problems with blood clotting

In a study comparing CARVYKTI® to standard therapy, there was a higher rate of death in the first 10 months in the CARVYKTI® arm (14%) compared to the standard therapy arm (12%). The increased rate of deaths occurred before receiving CARVYKTI® and after treatment with CARVYKTI®. The reasons for death were progression of multiple myeloma and side effects of the treatment.

CARVYKTI® can cause a very common side effect called cytokine release syndrome, or CRS, which can be severe or fatal. Symptoms of CRS include fever, difficulty breathing, dizziness or lightheadedness, nausea, headache, fast heartbeat, low blood pressure, or fatigue. Tell your healthcare provider right away if you develop fever or any of these other symptoms after receiving CARVYKTI®.

CARVYKTI® can increase the risk of life-threatening infections, including COVID-19, that may lead to death. Tell your healthcare provider right away if you develop fever, chills, or any signs or symptoms of an infection.

CARVYKTI® can cause various neurologic side effects, some of which may be severe or fatal. Symptoms include but are not limited to confusion, disorientation, loss of consciousness, seizures, difficulty speaking, reading or writing, tremor, slower movements, changes in personality, depression, tingling and numbness of hands and feet, leg and arm weakness, and facial numbness.

CARVYKTI® can lower one or more types of your blood cells (red blood cells, white blood cells, or platelets [cells that help blood to clot]), which may make you feel weak or tired, or increase your risk of severe infection or bleeding that may lead to death. After treatment, your healthcare provider will test your blood to check for this. Tell your healthcare provider right away if you get a fever, chills, or any signs or symptoms of an infection, are feeling tired, or have bruising or bleeding.

CARVYKTI® can cause serious gastrointestinal side effects, including severe or persistent diarrhea or ruptured bowel, which can be life-threatening and may lead to death. Tell your healthcare provider right away if you develop diarrhea, abdominal pain, weight loss, fever, chills, or any signs or symptoms of an infection.

CARVYKTI® may increase your risk of getting cancers, including certain types of blood cancers. Your healthcare provider should monitor you for this.

Having CARVYKTI® in your blood may cause some commercial Human Immunodeficiency Virus (HIV) tests to incorrectly give you an HIV-positive result even though you may be HIV-negative.

These are not all the possible side effects of CARVYKTI®. Call your healthcare provider if you have any side effects.

You may report side effects to FDA at 1-800-FDA-1088.

Please read full [Prescribing Information](#), including Boxed Warning, for CARVYKTI®.



MyCARVYKTI® Patient Support Specialists are here to help.

To enroll in MyCARVYKTI® and confirm if you are eligible, or to learn more, call **800-559-7875, option 1**, Monday through Friday, 8:00 AM to 8:00 PM ET.



WWW.CARVYKTI.COM

© Johnson & Johnson and its affiliates 2025

© Legend Biotech 2025

All rights reserved. 11/25 cp-263555v9

**Johnson
& Johnson**

 **LEGEND**
BIOTECH